Literature DB >> 25195764

World Federation of Societies of Biological Psychiatry guidelines for the pharmacological treatment of dementias in primary care.

Ralf Ihl1, Robertas Bunevicius, Lutz Frölich, Bengt Winblad, Lon S Schneider, Bruno Dubois, Alistair Burns, Florence Thibaut, Siegfried Kasper, Hans-Jürgen Möller.   

Abstract

OBJECTIVE: To define a practice guideline for biological treatment of dementias for general practitioners in primary care.
METHODS: This paper is a short and practical summary of the World Federation of Biological Psychiatry (WFSBP) guidelines for the Biological treatment of Alzheimer's disease and other dementias for treatment in primary care ( Ihl et al. 2011 ). The recommendations were developed by a task force of international experts in the field and are based on randomized controlled studies.
RESULTS: Anti-dementia medications neither cure, nor arrest, or alter the course of the disease. The type of dementia, the individual symptom constellation and the tolerability and evidence for efficacy should determine what medications should be used. In treating neuropsychiatric symptoms, psychosocial intervention should be the treatment of first choice. For neuropsychiatric symptoms, medications should only be considered when psychosocial interventions are not adequate and after cautious risk-benefit analysis.
CONCLUSIONS: Depending on the diagnostic entity and clinical presentation different anti-dementia drugs can be recommended. These guidelines provide a practical approach for general practitioners managing dementias.

Entities:  

Keywords:  Alzheimer's disease; Dementia; Lewy body disease; anti-dementia drugs; guidelines; neuropsychiatric symptoms

Mesh:

Substances:

Year:  2014        PMID: 25195764     DOI: 10.3109/13651501.2014.961931

Source DB:  PubMed          Journal:  Int J Psychiatry Clin Pract        ISSN: 1365-1501            Impact factor:   1.812


  5 in total

Review 1.  The rationale for deep brain stimulation in Alzheimer's disease.

Authors:  Zaman Mirzadeh; Ausaf Bari; Andres M Lozano
Journal:  J Neural Transm (Vienna)       Date:  2015-10-06       Impact factor: 3.575

2.  Ovocystatin Induced Changes in Expression of Alzheimer's Disease Relevant Proteins in APP/PS1 Transgenic Mice.

Authors:  Bartlomiej Stanczykiewicz; Jakub Gburek; Maria Rutkowska; Marta Lemieszewska; Krzysztof Gołąb; Katarzyna Juszczyńska; Aleksandra Piotrowska; Tadeusz Trziszka; Piotr Dzięgiel; Marzenna Podhorska-Okołów; Agnieszka Zabłocka; Joanna Rymaszewska
Journal:  J Clin Med       Date:  2022-04-23       Impact factor: 4.964

Review 3.  An Overview of Systematic Reviews of Ginkgo biloba Extracts for Mild Cognitive Impairment and Dementia.

Authors:  Hong-Feng Zhang; Li-Bo Huang; Yan-Biao Zhong; Qi-Hui Zhou; Hui-Lin Wang; Guo-Qing Zheng; Yan Lin
Journal:  Front Aging Neurosci       Date:  2016-12-06       Impact factor: 5.750

Review 4.  Amyloid-beta immunotherapy: the hope for Alzheimer disease?

Authors:  Alvaro Barrera-Ocampo; Francisco Lopera
Journal:  Colomb Med (Cali)       Date:  2016-12-30

Review 5.  Treatment of dementia and mild cognitive impairment with or without cerebrovascular disease: Expert consensus on the use of Ginkgo biloba extract, EGb 761®.

Authors:  Nagaendran Kandiah; Paulus Anam Ong; Turana Yuda; Li-Ling Ng; Kaysar Mamun; Reshma Aziz Merchant; Christopher Chen; Jacqueline Dominguez; Simeon Marasigan; Encarnita Ampil; Van Thong Nguyen; Suraya Yusoff; Yee Fai Chan; Fee Mann Yong; Orapitchaya Krairit; Chuthamanee Suthisisang; Vorapun Senanarong; Yong Ji; Ramesh Thukral; Ralf Ihl
Journal:  CNS Neurosci Ther       Date:  2019-02       Impact factor: 5.243

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.